期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 3, 页码 279-293出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2016.1146591
关键词
developmental delay; neurodevelopmental disorder; ADHD; autism spectrum disorder; children; adolescent; comorbidity; ASD
资金
- Pfizer
- Ironshore
- Shire
- Akili Interactive Labs
- CogCubed
- Alcobra
- VAYA Pharma
- Neurovance
- Impax
- NeuroLifeSciences
- Otsuka
- McNeil
- Janssen
- Novartis
- Eli Lilly
Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) commonly co-occur. With the DSM-5, clinicians are permitted to make an ASD diagnosis in the context of ADHD. In earlier versions of the DSM, this was not acceptable. Both ASD and ADHD are reported to have had substantial increases in prevalence within the past 10 years. As a function of both the increased prevalence of both disorders as well as the ability to make an ASD diagnosis in ADHD, there has been a significant amount of research focusing on the comorbidity between ADHD and ASD in the past few years. Here, we provide an update on the biological, cognitive and behavioral overlap/distinctiveness between the two neurodevelopmental disorders with a focus on data published in the last four years. Treatment strategies for the comorbid condition as well as future areas of research and clinical need are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据